1. Home
  2. OMER vs NNDM Comparison

OMER vs NNDM Comparison

Compare OMER & NNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • NNDM
  • Stock Information
  • Founded
  • OMER 1994
  • NNDM 2012
  • Country
  • OMER United States
  • NNDM United States
  • Employees
  • OMER N/A
  • NNDM N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • NNDM Electrical Products
  • Sector
  • OMER Health Care
  • NNDM Technology
  • Exchange
  • OMER Nasdaq
  • NNDM Nasdaq
  • Market Cap
  • OMER 304.9M
  • NNDM 308.5M
  • IPO Year
  • OMER 2009
  • NNDM N/A
  • Fundamental
  • Price
  • OMER $4.06
  • NNDM $1.48
  • Analyst Decision
  • OMER Strong Buy
  • NNDM
  • Analyst Count
  • OMER 5
  • NNDM 0
  • Target Price
  • OMER $18.00
  • NNDM N/A
  • AVG Volume (30 Days)
  • OMER 730.2K
  • NNDM 1.7M
  • Earning Date
  • OMER 11-12-2025
  • NNDM 09-17-2025
  • Dividend Yield
  • OMER N/A
  • NNDM N/A
  • EPS Growth
  • OMER N/A
  • NNDM N/A
  • EPS
  • OMER N/A
  • NNDM N/A
  • Revenue
  • OMER N/A
  • NNDM $58,812,000.00
  • Revenue This Year
  • OMER N/A
  • NNDM N/A
  • Revenue Next Year
  • OMER N/A
  • NNDM N/A
  • P/E Ratio
  • OMER N/A
  • NNDM N/A
  • Revenue Growth
  • OMER N/A
  • NNDM 7.49
  • 52 Week Low
  • OMER $2.95
  • NNDM $1.31
  • 52 Week High
  • OMER $13.60
  • NNDM $2.74
  • Technical
  • Relative Strength Index (RSI)
  • OMER 46.53
  • NNDM 56.96
  • Support Level
  • OMER $4.07
  • NNDM $1.39
  • Resistance Level
  • OMER $4.20
  • NNDM $1.53
  • Average True Range (ATR)
  • OMER 0.17
  • NNDM 0.06
  • MACD
  • OMER -0.04
  • NNDM 0.01
  • Stochastic Oscillator
  • OMER 24.49
  • NNDM 72.73

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About NNDM Nano Dimension Ltd.

Nano Dimension Ltd provide industrial manufacturing solutions for design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research and academia, along with government organizations.

Share on Social Networks: